Tiwari Rajan Kumar, Rawat Shiv Govind, Rai Siddharth, Kumar Ajay
Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
School of Medicine and Health Sciences, The George Washington University, Washington DC, USA.
Endocrine. 2025 May;88(2):359-386. doi: 10.1007/s12020-025-04161-7. Epub 2025 Jan 27.
The word "cancer" evokes myriad emotions, ranging from fear and despair to hope and determination. Cancer is aptly defined as a complex and multifaceted group of diseases that has unapologetically led to the loss of countless lives and affected innumerable families across the globe. The battle with cancer is not only a physical battle, but also an emotional, as well as a psychological skirmish for patients and for their loved ones. Cancer has been a part of our history, stories, and lives for centuries and has challenged the ingenuity of health and medical science, and the resilience of the human spirit. From the early days of surgery and radiation therapy to cutting-edge developments in chemotherapeutic agents, immunotherapy, and targeted treatments, the medical field continues to make significant headway in the fight against cancer. However, even after all these advancements, cancer is still among the leading cause of death globally. This urges us to understand the central hallmarks of neoplastic cells to identify novel molecular targets for the development of promising therapeutic approaches. Growing research suggests that stress mediators, including epinephrine, play a critical role in the development and progression of cancer by inducing neoplastic features through activating adrenergic receptors, particularly β-adrenoreceptors. Further, our experimental data has also shown that epinephrine mediates the growth of T-cell lymphoma by inducing proliferation, glycolysis, and apoptosis evasion via altering the expression levels of key regulators of these vital cellular processes. The beauty of receptor-based therapy lies in its precision and higher therapeutic value. Interestingly, the enhanced expression of β-adrenergic receptors (ADRBs), namely ADRB2 (β2-adrenoreceptor) and ADRB3 (β3-adrenoreceptor) has been noted in many cancers, such as breast, colon, gastric, pancreatic, and prostate and has been reported to play a pivotal role in facilitating cancer growth mainly by promoting proliferation, evasion of apoptosis, angiogenesis, invasion and metastasis, and chemoresistance. The present review article is an attempt to summarize the available findings which indicate a distinct relationship between stress hormones and cancer, with a special emphasis on epinephrine, considered as a key stress regulatory molecule. This article also discusses the possibility of using beta-blockers for cancer therapy.
“癌症”这个词引发了无数情绪,从恐惧和绝望到希望与决心。癌症被恰当地定义为一组复杂且多面的疾病,它无情地导致了无数生命的消逝,并影响了全球无数家庭。与癌症的斗争不仅是一场身体上的战斗,对患者及其亲人来说,也是一场情感和心理上的较量。几个世纪以来,癌症一直存在于我们的历史、故事和生活中,它挑战着健康和医学科学的智慧,以及人类精神的韧性。从早期的手术和放射治疗到化疗药物、免疫疗法和靶向治疗的前沿发展,医学领域在对抗癌症的斗争中不断取得重大进展。然而,即便有了所有这些进步,癌症仍是全球主要的死亡原因之一。这促使我们去了解肿瘤细胞的核心特征,以便确定有前景的治疗方法的新分子靶点。越来越多的研究表明,包括肾上腺素在内的应激介质通过激活肾上腺素能受体,特别是β - 肾上腺素能受体,诱导肿瘤特征,从而在癌症的发生和发展中发挥关键作用。此外,我们的实验数据还表明,肾上腺素通过改变这些重要细胞过程的关键调节因子的表达水平,诱导增殖、糖酵解和凋亡逃避,从而介导T细胞淋巴瘤的生长。基于受体的治疗的美妙之处在于其精确性和更高的治疗价值。有趣的是,在许多癌症中,如乳腺癌、结肠癌、胃癌、胰腺癌和前列腺癌,都发现β - 肾上腺素能受体(ADRB),即ADRB2(β2 - 肾上腺素能受体)和ADRB3(β3 - 肾上腺素能受体)的表达增强,据报道它们主要通过促进增殖、逃避凋亡、血管生成、侵袭和转移以及化疗耐药性,在促进癌症生长中发挥关键作用。本综述文章试图总结现有研究结果,这些结果表明应激激素与癌症之间存在明显关系,特别强调了被视为关键应激调节分子的肾上腺素。本文还讨论了使用β受体阻滞剂进行癌症治疗的可能性。